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Abstract
This review briefly notes recent findings important for understanding the surface mechanical functions of pulmonary
surfactant. Currently known surfactant-specific proteins and lipids are discussed, with an eye to their possible functions.
Competing models of the alveolar subphase life cycle of surfactant are also presented. It is concluded that, in spite of much
effort, we still do not understand the basic molecular mechanisms underlying surfactant’s rapid adsorption to the air-water
interface. ß 1998 Elsevier Science B.V. All rights reserved.
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1. Introduction
It is well over 40 years since Pattle revived interest
in pulmonary surfactant [1] and perhaps a good time
to see where we ¢nd current investigators working.
This chapter on surfactant composition and function
has been limited to introducing some issues related to
its surface activity, leaving subsequent authors to ¢ll
in many of the details. Surfactant functions other
than its surface activity have similarly been side-
stepped in this chapter but are covered in depth later
in this special issue of Biochimica et Biophysica Acta.
An excellent recent review of all surfactant functions
is available [2].
2. Surfactant distribution
2.1. Surfactant source
The source for most studies of surfactant compo-
sition has been bronchoalveolar lavage [2]. The same
lipid and protein components appear in analyses of
human and other mammalian species [3,4] with pro-
portions of di¡erent lipid classes varying somewhat,
perhaps due to methodological di¡erences. Many of
the principal lipids found in mammals are also found
in the lungs of air-breathing ¢shes [5], so ‘pulmonary’
surfactant may have a long history.
2.2. In airways and alveolar monolayer
Some surfactant components [6], or their e¡ects
[7], have been seen in the tracheobronchial tree, but
the mass of material retrieved by lavage probably
originates in the alveoli. The alveolar air-water sur-
face ¢lm is the site of surfactant’s major action on
lung mechanics, but its visualization there has proven
di⁄cult. Nevertheless, an innovative technique using
£uorocarbon £uid to deliver the ¢xative osmium te-
troxide could discern regions of up to seven stacked,
presumably single lipid layers at what was once the
£uorocarbon-water interface [8]. Whether continuous
multilayers always line the air-water interface is still
a matter of conjecture, however.
2.3. In aqueous alveolar subphase
In a recent scanning electron micrographic study
of rat lungs, the aqueous alveolar subphase lying
beneath the interface ¢lm had an average thickness
of 0.14 Wm over £at alveolar walls, and 0.89 Wm in
alveolar corners, for an area-weighted average thick-
ness of 0.2 Wm [9]. It appeared continuous, without
evident breaks. Fig. 1 is a transmission electron mi-
crograph of adult rat alveolar subphase, showing la-
mellar bodies (LB) apparently recently released from
type II cells, tubular myelin (TM) in the process of
being stitched together by a ‘quilting bee’ of several
lamellar bodies, and many particles of presumed
‘used’ surfactant. The relations of these surfactant
compartments are discussed below.
3. Surfactant composition
3.1. Fractionation of bronchoalveolar lavage
Bronchoalveolar lavage has commonly been sepa-
rated into subfractions by di¡erential centrifugation,
with the most dense fractions being enriched in tub-
ular myelin [10]. In associated tracer experiments
these tubular myelin-rich fractions also appeared to
be labeled earlier than the remaining liposomal frac-
tions. In more recent studies, Gross and associates
centrifuged mouse bronchoalveolar lavage to equili-
brium on continuous sucrose gradients, producing
three rather distinct fractions: an ‘ultraheavy’ frac-
tion (9 weight %) consisting of large aggregates of
tubular myelin with what appeared to be lamellar
bodies, a ‘heavy’ fraction (48%) with large empty
vesicles and some tubular myelin, and a ‘light’ frac-
tion (43%) consisting of small unilamellar vesicles
[11]. They further demonstrated that cyclic adsorp-
tion/desorption at the air-water interface somehow
converted the ultraheavy into the light fraction in a
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process that may possibly involve esterase activity.
Surfactant is now more commonly separated by dif-
ferential centrifugation into only two fractions,
deemed heavy and light subtypes.
3.2. Lipid composition
Lipids, particularly phospholipids, make up the
bulk of materials retrieved by bronchoalveolar lavage
[2]. Although phosphatidylcholine predominates
among the phospholipids, phosphatidylglycerol is
present in amounts up to 10 mol%, and smaller
amounts of phosphatidylethanolamine, phosphatid-
ylinositol, phosphatidylserine and the plasmalogen
analog of phosphatidylcholine are also present. Lipid
analysis most recently seems to involve high-per-
formance liquid chromatography, with [12] or with-
out [6,13,14] derivatization, although thin-layer fol-
lowed by gas chromatography is still used [15].
Investigators using these last techniques have found
that alveolar surfactant subfractions may di¡er
somewhat in their lipid composition.
Among the phosphatidylcholines, dipalmitoyl-
phosphatidylcholine (DPPC) predominates, making
Fig. 1. Particles in the alveolar subphase. In this electron micrograph section of a rat lung, lamellar bodies (LB) are seen forming tub-
ular myelin (TM) (bar at lower right = 1.0 Wm). The remaining vesicular structures may represent both used and rejected surfactant
materials. Inset: detail of tubular myelin at lower left, showing small projections in the corners, thought to represent SP-A
(bar = 0.1 Wm). This adult rat was exposed to NO2 for 48 h, but no di¡erences were seen from controls.
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up 41^70% of phosphatidylcholine [2,16]. Fatty acid
saturation has been assayed by a variety of methods,
perhaps explaining the very large deviation in re-
ported saturation indices between and even within
animal species. A method using osmium tetroxide
to oxidize or complex unsaturated phospholipids,
leaving behind the fully saturated species, has been
popular because of its simplicity [17,18], but high-
performance liquid chromatography is also fre-
quently employed [12,13,16]. Recently Holm et al.
have questioned the osmium method in a study com-
paring it with more traditional gas chromatographic
techniques [19]. Perhaps uncertainties with the meth-
od have contributed to the same group ¢nding that
the pool sizes for saturated phosphatidylcholine is
1.9 Wmol/kg in humans [3], 8 Wmol/kg in mice [20],
and 11.3 Wmol/kg in adult sheep [4]. Values obtained
using the osmium method for rabbit surfactant, 5.2
Wmol/kg [10], have also fallen within this range.
Based on his own experience comparing several var-
iants of the osmium method with gas chromatogra-
phy of derived fatty acid methyl esters, the author is
inclined to choose the latter, somewhat more labori-
ous method for determination of phospholipid satu-
ration. While the values noted above for di¡erent
species may be accurate, a reality check is provided
by the fact that a close packed DPPC ¢lm has a
molecular area of about 38 Aî 2. Assuming an adult
human’s alveolar area of 1.0 m2/kg body weight, one
would predict that a fully compressed ¢lm at func-
tional residual capacity would contain approx. 5
Wmol saturated phosphatidylcholine per kg. This val-
ue lies between the human and sheep values cited
above, and of course would not account for ‘multi-
layers’ of surfactant at the interface or any alveolar
subphase particles.
Cholesterol is also present in amounts up to 8
weight % (15 mol%), in addition to trace amounts
of triglycerides and free fatty acids.
3.3. Protein composition
Surfactant-speci¢c proteins make up about 10
weight % of material retrieved from bronchoalveolar
lavage. An excellent recent review of their properties
is available [21].
Surfactant proteins A and D (SP-A and SP-D)
represent the larger of the two subgroups. They are
members of the Ca2-dependent carbohydrate-bind-
ing collectin family, and will be discussed in great
depth in later chapters of this issue. The unique elec-
tron microscopic morphology of both SP-A and -D
has yet to be linked to their surface activity [22].
SP-D mRNA and protein have been detected in
mouse alveolar type II and non-ciliated bronchiolar
epithelial cells, as well as in cells of the tracheal
epithelium and submucosal glands [23].
Surfactant proteins B and C (SP-B and SP-C) are
extremely hydrophobic in nature and were found in
heavy but not light surfactant subfractions separated
by di¡erential centrifugation [24]. SP-B is usually
present as a dimeric structure, and SP-C is found
as thio-esters of one or more fatty acids [25]. SP-C
has also been found in association with isolated al-
veolar type II cells [26].
4. Surfactant surface activity
The author has limited himself to discussing pul-
monary surfactant’s surface tension lowering func-
tion, leaving the growing list of its other roles to later
chapters in this issue.
4.1. Models of the life cycle of alveolar surfactant
4.1.1. Physicochemical and physiological constraints
Surface ¢lms are obliged to follow certain physi-
cochemical constraints, and adequate pulmonary sur-
factant ¢lms in particular must produce appropriate
physiological behavior [27]. For example, a given
material in the alveolar subphase will not adsorb
into the air-water interface unless ¢lm surface tension
is above the equilibrium value for that material.
When conditions are appropriate for adsorption to
occur, a good lung surfactant usually adsorbs very
rapidly, with a time constant measured in millisec-
onds. This process most often requires a deep breath
(e.g., a sigh) and will generally not occur during quiet
tidal breathing. Only when a surface ¢lm is com-
pressed below the equilibrium surface tension of a
particular component, will there be a net desorption
of that component from the surface ¢lm. In good,
physiologically functioning lung surfactant ¢lms, this
process is usually very slow, with a time constant
measured in hours.
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4.1.2. Commonly accepted parts of the life cycle
The following commonly accepted steps followed
by alveolar components in the subphase can be seen
along with some more controversial paths in Fig. 2.
1. Secretion of LB into alveolar subphase from type
II cells.
2. Formation of TM, usually from multiple LB.
3. Rapid adsorption of TM into the interface, form-
ing a ¢lm.
4. Compression of ¢lm, lowering surface tension.
5. Eventual slow collapse of low tension ¢lm into
subphase.
6. Retrieval of used subphase surfactant by type II
cells.
7. Similar retrieval by macrophages (not shown).
8. Repackaging of retrieved materials into new LB.
4.1.3. The author’s preferred changes to the life cycle
The following modi¢cations seem likely to the au-
thor, and are based on what the author believes to be
important recent observations by others. They are
diagrammed in Fig. 2, to the right of the dashed
line under ‘AIR’.
(3a) Sorting of surfactant during adsorption of
TM forms a DPPC-rich ¢lm [28,29] and DPPC-
poor lipid-protein particles in the subphase.
(5a) Slow collapse of the DPPC-rich ¢lm contrib-
utes to DPPC-rich particulate forms in the subphase
and possibly to a surface-associated phase (SAP)
which remains in close proximity to the active ¢lm
[30].
4.1.4. The more widely accepted version of the model
These modi¢ed steps are portrayed on the left-
Fig. 2. Two models of the life cycle of pulmonary surfactant in the alveolar subphase. The left-hand half of the diagram (thin arrows)
represents the most widely accepted model of the cycle, the right-hand half (thick arrows) represents the author’s current biased views.
An alveolar type II cell sits at the bottom of the ¢gure, releasing lamellar bodies (LB), which are transformed into tubular myelin
(TM). During deep inspiration, materials adsorb extremely rapidly from TM to the ¢lm in the air-water interface at the top, and dur-
ing expiration the ¢lm is compressed to the low surface tensions that promote alveolar stability. Losses from the surface into the sub-
phase at various stages are recycled by type II cells into new lamellar bodies (dashed arrows). Both models produce a DPPC-rich ¢lm
at near zero surface tension (Q, upper right and left of ¢gure), and both produce a surface-associated phase (S.A.P.) and DPPC-rich
and -poor particles for eventual type II cell retrieval. The right-hand model di¡ers from the left in that it sorts DPPC-rich lipids di-
rectly into the ¢lm during adsorption, whereas the left-hand model must compress (Compr) the ¢lm several times in order to convert
an initially mixed-lipid ¢lm into one that is DPPC-enriched. The sequential compressions squeeze non-DPPC components out of the
¢lm, perhaps into the surface associated phase. Possible reentry of material into the ¢lm is also indicated (*). Some likely inter-particle
and particle-¢lm transfers are indicated by the arrows, but other possible arrows have been eliminated in the interests of clarity.
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hand side of Fig. 2, and represent the current, tradi-
tional view of the surfactant cycle [2].
(3b) All TM components adsorb into the initial
¢lm.
(3.5b) The surface-associated phase can readsorb
to the air-water interface (arrow with asterisk).
(4b) Compression/expansion cycles purify the ¢lm
during tidal breathing by squeezing out most non-
DPPC components into the surface associated phase
and aqueous particulate phases [31].
The author believes that these last steps may in-
deed occur in special circumstances, but that they are
not found during normal physiologic breathing.
They may be regarded as ‘back-up’ mechanisms dur-
ing situations of surfactant shortage. He feels that
during normal ventilation, tubular myelin usually
places DPPC into the interface too fast for compet-
ing readsorption of used surfactant to be quantita-
tively signi¢cant. If the author’s belief is indeed true,
then it is likely that most surface balance studies of
pulmonary surfactant components involving solvent
spreading of mixed monolayers are actually study-
ing this ‘traditional’ model to the exclusion of the
sorting model. Since a normal newborn’s lungs do
not collapse during their ¢rst expiration, the initial
adsorbed air-water interface must somehow have
become enriched in DPPC during the prior inspi-
ration. If puri¢cation by several cycles of respiration
were required, some lung collapse would have to
occur before a usable working ¢lm would be
achieved.
4.2. The e¡ects of surfactant function on pulmonary
physiology
4.2.1. Pulmonary mechanics
Beyond the importance of low alveolar surface
tension in promoting lung stability [27], one should
also consider the e¡ects of surfactant adsorption and
desorption kinetics on surfactant function. More
detailed kinetic studies and some computer
model-building will be required [32,33]. Clinically
evident repetitive collapse and re-expansion of
lungs may be a result of kinetic dysfunctions [34],
and a better understanding of lung damage from
overin£ation should follow a better picture of
how surfactant function is linked to mechanics
[35,36].
4.2.2. Surfactant in airways
Surfactant also has roles to play in small airways.
Thus it can act to maintain patency [37], to prevent
resistance increase in allergen-challenged animals
[38], and to enhance mucociliary clearance of un-
wanted contaminants [7,39].
4.2.3. Pulmonary vessels and blood £ow
Not surprisingly, surfactant e¡ects on lung me-
chanics have also been found to produce concomi-
tant lung circulatory changes [40].
4.3. Means of assessing alveolar-stabilizing function
of surfactant
Adequately measuring surfactant function in vitro
and in vivo has proven to be very di⁄cult. Di¡erent
techniques are required to answer di¡erent questions,
one size does not ¢t all.
4.3.1. Wilhelmy balance
The modi¢ed Langmuir-Wilhelmy surface balance,
usually consisting of a Te£on trough with either
tightly ¢tting or ribbon barriers, has been used for
a longer time than most other lung surfactant meth-
ods, and is still being suitably employed. For exam-
ple, recent work on the respreading of used surfac-
tant has made appropriate use of this technique [41].
4.3.2. Captive bubble surfactometer
Because ¢lms with very low tensions could not be
adequately contained in Langmuir-Wilhelmy balan-
ces at physiological temperatures, Schu«rch and col-
leagues developed several models of a captive bubble
surfactometer [42^44]. The use of such a balance was
critical in demonstrating the importance of low ¢lm
compressibility as an indicator of good surfactant
function [29]. Reaching near-zero surface tension
with a mere 15^20% ¢lm area compression is prob-
ably the most di⁄cult goal to achieve, and represents
the hallmark of excellent surfactant function. It is
becoming apparent from these in vitro studies that
surfactant concentrations of at least 1 mg phospho-
lipid/ml must be present to obtain optimal results.
4.3.3. Pulsating bubble surfactometer
The pulsating bubble surfactometer, developed by
Enhorning [45], is a predecessor of the captive bubble
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device, and is still in more common use in spite of
some surface leakage di⁄culties. It o¡ers a much
smaller sample size and far greater ease of use than
its derivative machine, but falls short when asked to
provide critical information from the ¢rst ¢lm com-
pression. A comparison of both bubble devices with
a recommendation for addressing surface leakage
problems with the pulsating bubble surfactometer
has been published [46]. Most studies using this latter
device ignore ¢rst compression isotherm data, and
report the lowest surface tensions found in 50^100
cyclic bubble compressions [47].
4.3.4. Administration of surfactants to preterm
animals, rabbits and lambs
Preterm rabbits and preterm lambs have increas-
ingly been used to study the in vivo e¡ects of surfac-
tant preparations. They provide excellent, ‘real-
world’ tests of function, and good comparisons be-
tween arti¢cial and natural products [48], free of the
many quali¢cations inherent to the above-described
in vitro methods.
4.3.5. Ethanol resistive microbubble test
Another microbubble method for assaying surfac-
tant [49] is quite closely related to the bubble behav-
ior originally described by Pattle [1], and o¡ers a
good opportunity to study ¢lm stability.
4.4. Function of surfactant fractions and individual
components
4.4.1. General concerns
We know something about what a few of the com-
ponents of surfactant can do in vitro, but almost
nothing about how they do it, even under such con-
trolled conditions. Our further linking of in vitro to
in vivo performance still relies largely on faith. Even
genetic knockouts have left us with more questions
than answers, given most animals’ superb means for
compensation of losses. A ‘rescued’ animal need not
be as normal as he appears, always bringing into
question the true physiologic function of the deleted
gene.
4.4.2. Functions of surfactant fractions
Heavier, tubular myelin-enriched preparations
studied in a surface balance, adsorb and spread
more rapidly and compress with smaller area changes
to low surface tensions than do ‘lighter’ small vesicle
preparations [10]. Lipid adsorption seems to be nec-
essary for conversion of heavy to light subfractions
[50]. Whereas Putman et al. [24] found that their
original bronchoalveolar lavage adsorbed rapidly,
neither their resuspended heavy nor light fractions
did so. They concluded that subtleties in the handling
surfactant materials can greatly a¡ect their proper-
ties. We have found repeatedly that careful, thor-
ough dispersion of heavy fractions destroys their
ability to adsorb very rapidly (unpublished observa-
tions), perhaps explaining the results of Putman et al.
4.4.3. Functions of individual components
4.4.3.1. Lipids. The active alveolar ¢lm seems to
be very highly enriched in DPPC compared to the
composition of bronchoalveolar lavage, although
pure DPPC suspensions have usually been found to
adsorb and spread extremely slowly at the air-water
interface. By preparing DPPC suspensions of large
particles in bu¡er at temperatures near 5‡C, however,
one can create a form that adsorbs rapidly in systems
at 37‡C (unpublished observations), hence the some-
times unknown physical state of any component may
greatly in£uence its surface properties. The particular
roles of the other lipid components remain uncertain
in spite of intensive study. For example, surface bal-
ance experiments involving solvent-spread lipid and
lipid/protein mixtures give suggestive evidence for the
possible in vivo behavior of non-DPPC surfactant
components [51,52], but generally such experimental
conditions do not closely replicate those in the lung.
4.4.3.2. Proteins. Hydrophobic apoproteins SP-B
and -C usually promote very rapid adsorption of
lipids to the air-water interface, and SP-A speeds
this process even further under certain circumstances.
These three surfactant proteins have also been found
to improve pulmonary function in a premature rab-
bit model [53].
SP-A and -D, the hydrophilic surfactant proteins,
both demonstrate unusual morphologies (Fig. 1),
and seem to aid the other proteins in promoting
adsorption [22]. Although binding studies indicate
strong interactions between surfactant proteins and
surfactant lipids, these ¢ndings have not led to any
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detailed understanding of surfactant proteins’ surface
tension-lowering function, although they do help us
understand better the uptake and release of surfac-
tant lipids by type II cells [54]. Some recent data
provide suggestions about mechanisms: phospholipid
membrane fusion is commonly taken as an indicator
of surfactant adsorption potential, and has been
found to be induced by both SP-A and -B [55], ad-
dition of SP-A to Curosurf, a commercial surfactant
replacement, can overcome added surfactant inhibi-
tors [56], and surface tension-area isotherms with
compression to near zero surface tension were con-
sistent with the interpretation that SP-D incorpo-
rated by adsorption was apparently not squeezed
out of the ¢lm [57].
SP-B and -C, the hydrophobic surfactant proteins,
accelerate adsorption of mixed surfactant lipids [58].
There is evidence that both proteins are required for
rapid adsorption of surfactant heavy fraction, but
that this activity can be lost during handling of sam-
ples [24] if large aggregates are disrupted. Both pro-
teins can form stable air-water monolayers by them-
selves or as mixtures with DPPC, and both (SP-
Bs SP-C) promote readsorption of materials from
collapsed, DPPC-containing monolayers [59,60].
Although some protein content was evidently
squeezed out of compressed monolayers, the retained
proteins did not prevent the reaching of near zero
surface tensions, and appeared to promote respread-
ing of lipid-protein on ¢lm expansion. The ¢lm asso-
ciation of these proteins was later con¢rmed using
£uorescent labels [61], although the labels could not
distinguish material in the adjacent subphase from
that retained within the monolayer ¢lm itself. Fur-
ther external re£ection absorption infrared spectro-
scopic data for SP-B and -C ¢lms show that SP-B is
more easily squeezed out than SP-C [62].
SP-B’s e¡ects have also been studied alone. For
example, antibody against SP-B produced deleterious
physiological e¡ects in near-term newborn rabbits
[63], and the positive charge on SP-B has been shown
to promote segregation of negatively charged lipids
within mixed-lipid monolayers [64]. This last action
may be a clue to the mechanism underlying the ap-
parent sorting behavior of tubular myelin during ad-
sorption.
SP-C-oriented studies show it to exist in palmitoyl-
ated and non-palmitoylated forms [65]. In investiga-
tions of the activity of the major acylated form ver-
sus non-acylated SP-C, palmitoylation was found to
enhance respreading and stability of mixed DPPC/
phosphatidylglycerol ¢lms in a captive bubble surfac-
tometer [66]. This same paper showed that low ¢lm
tensions could be achieved with the same lipid mix-
ture at very low pH without any proteins at all.
Others have shown that SP-C’s positively charged
residues are important for binding phospholipid
vesicles to the monolayer, preceding their insertion
[67], and that the hydrophobic C-terminal helix is
crucial for its rapid adsorption [68].
4.5. E¡ects of genetic manipulations and diseases
Selected modi¢cations of surfactant genes and
some human diseases often a¡ect surfactant in
ways that may help us understand more about the
function of its components.
4.5.1. Genetic manipulations of surfactant proteins
Much current research in surfactant uses newly
available, powerful genetic tools. In the ¢rst pub-
lished SP-A gene knockout, Korfhagen et al. found
that the animals survived, appeared grossly normal
and had normal lung function, although tubular
myelin ¢gures were decreased in number [69]. Mini-
mum surface tensions of compressed ¢lms from cen-
trifuged bronchoalveolar lavage were the same for
wild type and knockout at higher concentrations,
but somewhat higher for knockouts at low concen-
trations. A follow-up paper found that tissue and
alveolar pools of saturated phosphatidylcholines
were actually larger in the knockout mice.
SP-B knockouts have produced more dramatic re-
sults. Homozygous null mice did not survive after
delivery unless rescued with SP-B proprotein or con-
tinually managed with liquid £uorocarbon ventila-
tion [70]. Heterozygous mice demonstrated decreased
lung compliance and air trapping secondary to air-
way collapse [71]. In both sets of mice, SP-A, -C and
-D were present in normal amounts. Surfactant pools
of saturated phosphatidylcholine were also normal in
these mice [72].
To date no SP-C knockouts have been reported.
Conservation of its gene has been strong throughout
evolution [73], so SP-C is likely to prove valuable for
function and survival.
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4.5.2. Association with diseases
The respiratory distress syndrome of the newborn
has long been associated with prematurity, but there
appears to be at least one genetic predisposition as
well. Floros et al. have found a signi¢cant increase in
the incidence of SP-B variants among respiratory
distress infants [74], perhaps indicating an increased
susceptibility to the disease due to SP-B inadequacy.
Surface balance data for these variants have not been
published as yet. To date the acute (often called
‘adult’) form of the respiratory distress syndrome
has not been linked to genetic defects, but bronchoal-
veolar lavage of these patients has been found to
contain lowered heavy/light fraction ratios, with de-
creased SP-A content in the heavy fractions [75].
The bronchoalveolar lavage of patients with alveo-
lar proteinosis, a rare condition characterized by vol-
uminous amounts of lipid- and protein-rich material
in the airways, has been found to contain both nor-
mal and multimerized SP-A [76]. Further investiga-
tion has established that the abnormal SP-A aggre-
gates are associated with signi¢cant amounts of
immunoglobulin G [77], suggesting an immunologi-
cal basis for the condition. Silicosis in humans and
animals produces somewhat similar increases in
bronchoalveolar lipid and protein. Cell culture stud-
ies of rat type II alveolar cells [78] showed that silica
itself did not produce similar changes, but that bron-
choalveolar wash from silica-exposed animals pro-
duced an increase in lipid synthesis, a decrease in
secretion of surfactant materials, an increase in
DPPC reuptake by type II cells, and a decreased
uptake by alveolar macrophages.
In cystic ¢brosis, a disease of variously modi¢ed
ion transporter genes, bronchiolar lavage of infants
with associated pulmonary in£ammation or infection
showed the saturated phosphatidylcholine/total
phosphatidylcholine ratio to be lower and the SP-A
concentration to be higher than in either normals or
non-in£amed cystic ¢brosis patients [18]. A direct
surfactant involvement is thus found lacking at
present.
Smoking has also been studied for its possible ef-
fects on the surfactant system. Rats chronically ex-
posed to cigarette smoke showed signi¢cant de-
creases in total lavage SP-B, but SP-A and SP-B
mRNAs were not di¡erent from sham-exposed ani-
mals [79].
Other diseases will undoubtedly be linked to sur-
factant e¡ects in the future, but the alveolar pro-
teinosis/silicosis links seem most promising at present
for leads to the function of surfactant components.
5. Unresolved issues and future perspectives
Although pulmonary surfactant has been subjected
to very sophisticated analytical and experimental
techniques for over 40 years, we are still in the
dark as to how some of its basic actions take place
at a molecular level. In particular, the tools of sur-
face chemistry and other physicochemical sub¢elds,
and of molecular biology have not helped us discover
the detailed mechanisms by which selected surfactant
components can adsorb so very rapidly to the air-
water interface.
There are hints of these mechanisms in what we
already know, however. Genetic knockout experi-
ments and less leaky surface balances are teaching
us more about what the various surfactant compo-
nents can do, or more correctly, fail to do if they are
absent. There is even a new hint in the oft used
analogy between surface adsorption and liposomal
fusion. Very recently Weber et al. have successfully
tested a liposome model of protein-mediated mem-
brane fusion in neuronal exocytosis [80] in which
‘SNAREs, SNAPS, and SNAREpins’ all participate.
Is it too great a stretch of the imagination to envision
the present surfactant lipids and proteins or even a
protein yet to be discovered (perhaps SP-V = VEL-
CRIN) playing similar roles at the air-water surface?
Time will tell.
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